Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Volitionrx (VNRX) EBIT (2019 - 2025)

Historic EBIT for Volitionrx (VNRX) over the last 9 years, with Q3 2025 value amounting to -$5.1 million.

  • Volitionrx's EBIT rose 1308.15% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.7 million, marking a year-over-year increase of 2428.73%. This contributed to the annual value of -$27.0 million for FY2024, which is 2490.5% up from last year.
  • As of Q3 2025, Volitionrx's EBIT stood at -$5.1 million, which was up 1308.15% from -$6.3 million recorded in Q2 2025.
  • Volitionrx's 5-year EBIT high stood at -$5.1 million for Q3 2025, and its period low was -$9.5 million during Q2 2023.
  • Moreover, its 5-year median value for EBIT was -$7.7 million (2022), whereas its average is -$7.4 million.
  • In the last 5 years, Volitionrx's EBIT plummeted by 6788.6% in 2021 and then surged by 3414.37% in 2025.
  • Volitionrx's EBIT (Quarter) stood at -$8.8 million in 2021, then grew by 8.81% to -$8.0 million in 2022, then decreased by 9.11% to -$8.7 million in 2023, then surged by 33.86% to -$5.8 million in 2024, then grew by 11.77% to -$5.1 million in 2025.
  • Its EBIT stands at -$5.1 million for Q3 2025, versus -$6.3 million for Q2 2025 and -$5.5 million for Q1 2025.